My question, What is the estimated costs factor for DCVax-l if approved Copilot response, The estimated cost factor for DCVax-L, if approved, is expected to be substantially below the price range of most antibody drugs and “targeted” cancer drugs. These types of drugs are typically priced at around $60,000 to $80,000 per year, and in some cases, they can even exceed $100,000 per year1. To put this into context, let’s compare it to another cancer treatment:
DCVax-L, Brain Cancer World cancer data, Rank Cancer New cases in 2020 % of all cancers 19 Brain, central nervous system 308,102 1.7
Per year S-Curve timeline analysis costs based on only 25% market DCVax-L estimated costs $60,000.00 $80,000.00 S-Curve % (over two years) Patient's Total sales at $60K Total sales at $80K 2 6000 $360,000,000.00 $480,000,000.00 10 30000 $1,800,000,000.00 $2,400,000,000.00 25 75000 $4,500,000,000.00 $6,000,000,000.00 45 135000 $8,100,000,000.00 $10,800,000,000.00
What if DCVax-D is approved in a few years and can help cure all solid tumors for the leading cancers throughout the world? Now consider what for potential NVP for NWBO given approval for DCVax-D, IMPO.
World cancer data, Rank Cancer New cases in 2020 % of all cancers 1 Breast 2261419 12.5
Per year S-Curve timeline analysis costs based on only 25% market DCVax-D estimated costs $60,000.00 $80,000.00 S-Curve % (over two years) Patient's Total sales at $60K Total sales at $80K 2 45228 $2,713,702,800.00 $3,618,270,400.00 10 226142 $13,568,514,000.00 $18,091,352,000.00 25 565355 $33,921,285,000.00 $45,228,380,000.00 45 1017639 $61,058,313,000.00 $81,411,084,000.00
Now consider the other top cancer rates based on solid tumors. You get the picture, IMPO. The bottom line indicates the value of NWBO revenue (GBM) could value the stock price could be worth $16 to $25, DCVax-L, IMPO The bottom line indicates the value of NWBO revenue (Breast) could value the stock price could be worth $120 to $160, DCVax-D, IMPO Now add the other top 10 cancers based on solid tumor cancer could very well be worth 5X to 10X the value of DCVax-D alone, IMPO. Keep in mind, the S-Curve analysis is based on only a 25% market share and over a two year period for DCVax-L, IMPO. Keep in mind, the S-Curve analysis is based on only a 25% market share and over a two year period for DCVax-D, IMPO. You do the math, and you can clearly see that the overall potential value for NWBO's revenue and stock price could be worth hundreds of $$$ billions, IMPO. Praying for DCVax-L approval as soon as possible followed by DCVax-D approval as soon as possible.
Market Data 
Markets 
AI
